


SCAI PRESENTS



CASE-BASED FORUM:  
**Individualizing  
Antithrombotic  
Therapies for  
PCI Patients**

Sponsored by



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

Supported through an educational grant from **ASTRAZENECA**

# Disclosures

The faculty reported the following relevant financial relationships during the content development process for this activity:

**Sunil V. Rao, MD, FSCAI**

Nothing to disclose.

**Binita Shah, MD, FSCAI**

*Philips (Volcano):* Advisory Board; *Terumo:* Consulting

**Timothy D. Henry, MD, MSCAI**

*Caladrius Biosciences:* Advisory Board, Consulting

**David A. Cox, MD, MSCAI**

Nothing to disclose.

CME Oversight Committee reviewer **Babu Ezhumalai, MD, DM, FNB, FSCAI**, reported no financial relationships.

SCAI staff associated with the development of content for this activity, **Robert Bartel, MSc, FACEHP**, and **Laura Daigle Porter, CMP**, reported no relevant financial relationships.



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Accreditation Statement

The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SCAI designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Learning Objectives

- Upon completion of this activity, participants will be able to:
  - Select appropriate antiplatelet therapy for patients with coronary artery disease as well as polyvascular disease (PAD/CAD), continually integrating level-one evidence with clinical evaluation of risks and benefits
  - Recommend optimal antithrombotic regimens in patients with atrial fibrillation undergoing PCI
  - Review current data on antiplatelet needs of STEMI/NSTEMI patients
  - Formulate and adjust therapeutic plans for ACS patients at risk for bleeding events and/or acute coronary events
  - Manage the complicated ACS patient with diabetes, hypertension, and other coexisting disorders
  - Consult with primary care clinicians coordinating care of patients with ACS
  - Demonstrate decision-making in prevention of secondary cardiovascular disease
  - Describe the default DAPT duration for stable ischemic heart disease as well as after ACS
  - Determine proper stent selection for patients at high risk for bleeding



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Evaluation and Certificates

- Evaluations are available through the SCAI 2019 app.
- Please claim credit within 30 days of the meeting.



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Agenda

**Moderator:** Sunil V. Rao, MD, FSCAI

**Introduction and review of existing gaps in preventing thrombotic events for patients undergoing cardiovascular interventions**

*Sunil V. Rao, MD, FSCAI*

**Case 1. Stable outpatient with suspected multivessel coronary artery disease presenting for diagnostic coronary angiography**

*Sunil V. Rao, MD, FSCAI*

**Case 2. Patient presents to the ER on weekend with an NSTEMI**

*Binita Shah, MD, FSCAI*

**Case 3. STEMI patient with a history of diabetes arrives to the ER and will require primary PCI**

*Timothy D. Henry, MD, MSCAI*

**Case 4. A patient with a history of atrial fibrillation, already on warfarin presents to the ED with chest pain and rules in for NSTEMI. The patient is referred for early invasive risk stratification within 24 hours of admission.**

*David A. Cox, MD, MSCAI*



**SCAI**

Society for Cardiovascular  
Angiography & Interventions